Can-Fite BioPharma (CANF) Operating Expenses (2014 - 2023)

Can-Fite BioPharma (CANF) has 10 years of Operating Expenses data on file, last reported at -$2.0 million in Q4 2023.

• For the quarter ending Q4 2023, Operating Expenses fell 51.6% year-over-year to -$2.0 million; the trailing twelve-month figure through Dec 2023 stood at -$8.9 million (changed 0.0% YoY), and the FY2025 full-year result was -$10.4 million, down 17.62% from the prior year.
• Operating Expenses was -$2.0 million for Q4 2023 at Can-Fite BioPharma, up from -$2.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $2.0 million in Q1 2019 to a low of -$7.3 million in Q2 2019.
• A 5-year average of -$2.9 million and a median of -$2.8 million in 2022 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses sank 98.64% in 2019 and jumped 69.0% in 2022, its largest moves.
• Can-Fite BioPharma's Operating Expenses stood at -$4.8 million in 2019, then advanced by 22.9% to -$3.7 million in 2020, then retreated by 14.29% to -$4.2 million in 2021, then jumped by 69.0% to -$1.3 million in 2022, then tumbled by 51.6% to -$2.0 million in 2023.
• Per Business Quant data, the three most recent Operating Expenses figures were -$2.0 million in Q4 2023, -$2.1 million in Q3 2023, and -$2.0 million in Q2 2023.